scispace - formally typeset
A

Alexandre de Mendonça

Researcher at University of Lisbon

Publications -  216
Citations -  9347

Alexandre de Mendonça is an academic researcher from University of Lisbon. The author has contributed to research in topics: Frontotemporal dementia & Dementia. The author has an hindex of 43, co-authored 175 publications receiving 6752 citations. Previous affiliations of Alexandre de Mendonça include Sunnybrook Health Sciences Centre & Instituto de Medicina Molecular.

Papers
More filters
Journal ArticleDOI

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

TL;DR: The 6 years of extensive collaborative experiments and the analysis of hundreds of cell samples of patients and healthy controls have provided for the first time laboratory protocols and software tools for fully standardized 8-color flow cytometric immunophenotyping of normal and malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single database.
Journal ArticleDOI

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Céline Bellenguez, +401 more
- 01 Apr 2022 - 
TL;DR: This paper performed a two-stage genome-wide association study with 111,326 clinically diagnosed/proxy AD cases and 677,663 controls and found 75 risk loci, of which 42 were new at the time of analysis.
Journal ArticleDOI

Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests

TL;DR: When taking into account sensitivity, specificity and overall classification accuracy Random Forests and Linear Discriminant analysis rank first among all the classifiers tested in prediction of dementia using several neuropsychological tests.
Journal ArticleDOI

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

TL;DR: The use of the proposed research criteria to identify Alzheimer's disease at the mild cognitive impairment stage and the use of both amyloid and neuronal injury markers as proposed by the National Institute of Ageing-Alzheimer Association criteria offers the most accurate prognosis are supported.